Discover the solution to blurry vision due to Myopia with our Myopia lenses!
Myopia is currently a common refractive error globally which is causing vision loss and lastly blindness if left untreated. The economic burden globally is caused due to uncorrected refractive error, majorly due to myopia. If myopia is left untreated, the high myopic individuals have risk of developing early cataract, glaucoma, retinal pathologies like retinal detachment, macular degeneration, etc which is sight threatening. [1] Prevalence and incidence of myopia is noted more in the East Asian countries than other countries. [2]
Different optical treatment methodologies for Myopia Progression Control:
· Traditional spectacle lenses
· Peripheral defocus spectacle lenses (Example: MiYoSMART, STELLEST, MyoCare, etc)
· Traditional contact lenses
· Peripheral defocus soft contact lenses (Example: MiSight)
· Corneal reshaping contact lenses or Ortho-Keratology lenses
Myopia progression control spectacle lenses like MiYoSMART is based on the D.I.M.S. technology, STELLEST is based on the H.A.L.T technology and MyoCare is based on C.A.R.E. technology. Our blog mainly focuses on the C.A.R.E technology for myopia control. These lenses create a specific optical profile that minimizes peripheral blur, effectively guiding eye growth in a controlled manner. By integrating these advanced technologies, individuals can experience enhanced visual clarity while potentially mitigating future myopic development.Top of FormBottom of Form
Slowing the progression of myopia helps minimize the risk of developing serious eye health complications associated with high myopia. By controlling the elongation of the eyeball, peripheral defocus lenses can decrease the likelihood of conditions such as retinal detachment, macular degeneration, and glaucoma. These conditions are more prevalent in individuals with severe myopia, so effectively managing myopia progression can contribute to better long-term eye health and overall vision stability.
Zeiss MyoCare:
Zeiss MyoCare is the first myopia management technology built for particular age groups. C.AR.E. technology or Cylindrical Annular Refractive Elements technology aims to slow down myopic axial length elongation. It consists of alternate defocus and correction zones in a ring type pattern from center to the periphery of the lens. [3]
Types of Zeiss MyoCare lenses:
There are two types of C.A.R.E technology lenses – (a) MyoCare and (b) MyoCare S
MyoCare has a clear central zone of 7mm and mean additional surface power of +4.6D whereas MyoCare S has a clear central zone of 9mm and mean additional surface power of +3.8D. Ideally, MyoCare is advised for children younger than 10 years old and MyoCare S is advised for 10 years or older. [3]
How effective is Zeiss MyoCare technology?
Zeiss MyoCare technology has shown impressive effectiveness in clinical settings. Research indicates that these lenses can slow myopia progression by up to 50% compared to traditional single-vision lenses. Clinical trials have consistently demonstrated that MyoCare lenses effectively reduce the rate of eye elongation, a key factor in worsening myopia. This robust clinical evidence supports their use as a reliable option for managing myopia and potentially preventing severe vision complications in children. [4]
The ZEISS MyoCare designs show an average emmetropic progression ratio (a new approach to measure effectiveness) for axial length of:
up to 86% for children aged 10-12 years
up to 63% for children aged 7-9 years
References:
1. Holden BA, Fricke TR, Wilson DA, Jong M, Naidoo KS, Sankaridurg P, Wong TY, Naduvilath TJ, Resnikoff S. Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 2050. Ophthalmology. 2016 May;123(5):1036-42. doi: 10.1016/j.ophtha.2016.01.006. Epub 2016 Feb 11. PMID: 26875007.
2. Chen M, Wu A, Zhang L, Wang W, Chen X, Yu X, Wang K. The increasing prevalence of myopia and high myopia among high school students in Fenghua city, eastern China: a 15-year population-based survey. BMC Ophthalmol. 2018 Jul 3;18(1):159. doi: 10.1186/s12886-018-0829-8. PMID: 29970057; PMCID: PMC6029024.
4. Alvarez-Peregrina C, Sanchez-Tena MA, Martinez-Perez C, Villa-Collar C; Clinical Evaluation of MyoCare in Europe –the CEME Study Group; Ohlendorf A. Clinical Evaluation of MyoCare in Europe (CEME): study protocol for a prospective, multicenter, randomized, double-blinded, and controlled clinical trial. Trials. 2023 Oct 17;24(1):674. doi: 10.1186/s13063-023-07696-0. PMID: 37848908; PMCID: PMC10580514.
Bình luận